scholarly journals Pressure pain threshold and [beta]-endorphins plasma level are higher in lean polycystic ovary syndrome women

Author(s):  
Marta Kialka ◽  
Tomasz Milewicz ◽  
Sandra Mrozinska ◽  
Krystyna Sztefko ◽  
Iwona Rogatko ◽  
...  
2016 ◽  
Vol Volume 10 ◽  
pp. 2483-2490 ◽  
Author(s):  
Marta Kialka ◽  
Tomasz Milewicz ◽  
Krystyna Sztefko ◽  
Iwona Rogatko ◽  
Renata Majewska

2012 ◽  
Vol 28 (9) ◽  
pp. 722-725 ◽  
Author(s):  
Aydogan Aydogdu ◽  
Ilker Tasci ◽  
Serkan Tapan ◽  
Yalcin Basaran ◽  
Umit Aydogan ◽  
...  

2007 ◽  
Vol 7 (2) ◽  
pp. 173-178 ◽  
Author(s):  
Zulfo Godinjak ◽  
Ranka Javorić

The aim of study was to evaluate clinical outcome and hormone profiles of laparoscopic elec-troincision of the ovaries in women with polycystic ovary syndrome (PCOS) before and after treatment. Forty five clomiphene-citrate resistant women with polycystic ovary syndrome underwent laparoscopic electroincision of the ovaries. Serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone (T), androstenedione, 17 OH progesterone and beta endorphins were recorded before and 24 hours after the treatment. Clinical and reproductive outcome and hormone profiles were analyzed. Patients were observed during 12 months period. Laparoscopic electroincision of the ovaries was successfully performed without complications in all patients. LH/FSH ratio was 1,66 24 hours after treatment. Serum levels of T, androstenedione, 17 OH progesterone, and beta endorphins were significantly reduced 24 hours after laparoscopic electroincision of the ovaries. In follow-up period 87% of patients were recorded to have regular menstrual cycles and 61% pregnancy rate was achieved spontaneously. Laparoscopic electroincision of the ovaries is an effective treatment in clomiphene-citrate resistant women with polycystic ovary syndrome. The high pregnancy rate of the procedure offers a promising management for patients with polycystic ovary syndrome.


2016 ◽  
Vol 124 (01) ◽  
pp. 55-60 ◽  
Author(s):  
M. Kiałka ◽  
T. Milewicz ◽  
M. Spałkowska ◽  
M. Krzyczkowska-Sendrakowska ◽  
B. Wasyl ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Congcong Jin ◽  
Kexin Zou ◽  
Yue Xu ◽  
Haiyan Yang ◽  
Jiexue Pan

Abstract Background Pentraxin 3 (PTX3) - a crucial humoral innate immunity component – is related to obesity and cardiovascular complications in women who suffer from polycystic ovary syndrome (PCOS). However, the circulating PTX3 level in PCOS is still debated. In this study, we aimed to evaluate PTX3 plasma levels in PCOS women of childbearing age, and find possible endocrine/metabolic factors that could affect this level. Methods A total of 360 women were enrolled: 120 PCOS women and 240 body mass index (BMI) matched normally ovulating women. Blood samples were collected on the third day of natural menstrual cycle or from the bleeding after progesterone withdrawal. The PTX3 concentration was measured by immunoassay. Results The PTX3 plasma level was significantly higher in PCOS women compared to controls. There was a positive correlation between PTX3 plasma level and PCOS diagnosis, overweight, cycle length, serum LH to FSH ratio, estradiol, total testosterone (TT) on the third day of menstrual cycle, antral follicle count (AFC), as well as uric acid. Multivariant linear regression analysis indicated that participants’ serum PTX3 levels were proportional to the circulating TT level, existence of PCOS, basal estradiol level and AFC. Conclusions Overall, the circulating PTX3 level was elevated in PCOS women and significantly associated with the presence of hyperandrogenism. This study provided the basis for further in-depth researches regarding PTX3 role in PCOS pathophysiology.


2015 ◽  
Author(s):  
Marta Kialka ◽  
Magdalena Spalkowska ◽  
Tomasz Milewicz ◽  
Anna Pelka ◽  
Barbara Wasyl ◽  
...  

2011 ◽  
Vol 27 (12) ◽  
pp. 982-987 ◽  
Author(s):  
Jing Zhang ◽  
Lingling Zhou ◽  
Liulin Tang ◽  
Liangzhi Xu

Sign in / Sign up

Export Citation Format

Share Document